1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Title

Showing 1,267 results.

$Thumbnail for Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (Dara) ± Pomalidomide (Pom) vs Dara Plus Pom and Dexamethasone (DPd) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3$

MM - 593

Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (Dara) ± Pomalidomide (Pom) vs Dara Plus Pom and Dexamethasone (DPd) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3

Omik Patel

Poster Presenter: Omik Patel

Thumbnail for Phase A of the F-A-A Study: Derivation of a Bedside Functional Assessment-Age-Albumin Score for Predicting Induction Mortality in Patients With AML Receiving Low-Intensity Venetoclax-Based Therapy

AML - 927

Phase A of the F-A-A Study: Derivation of a Bedside Functional Assessment-Age-Albumin Score for Predicting Induction Mortality in Patients With AML Receiving Low-Intensity Venetoclax-Based Therapy

Rudra Narayan Swain

Poster Presenter: Rudra Narayan Swain

SOHO 2026 Annual Meeting

Posters by Title

Phase 3, Randomized Study of Talquetamab (Tal) Plus Daratumumab (Dara) ± Pomalidomide (Pom) vs Dara Plus Pom and Dexamethasone (DPd) in Relapsed/Refractory Multiple Myeloma (RRMM): MonumenTAL-3

Phase A of the F-A-A Study: Derivation of a Bedside Functional Assessment-Age-Albumin Score for Predicting Induction Mortality in Patients With AML Receiving Low-Intensity Venetoclax-Based Therapy

Phase III Randomized Evidence for BCMA-Directed CAR T-Cell Therapy Versus Standard Regimens in Relapsed/Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis

Phenotype-Specific Safety Differences Between Gilteritinib and Midostaurin in AML: A FAERS Analysis Highlighting Differentiation Syndrome Signal

Phenotype-Specific Safety Reporting Signals of Asciminib Versus Second- and Third-Generation Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A FAERS Disproportionality Analysis

Pirtobrutinib Following Covalent BTK Inhibitor Exposure in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Pooled Analysis

Pirtobrutinib in Treatment-Naοve (TN) Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Pooled Results From BRUIN CLL-313 and BRUIN CLL-314

Pirtobrutinib vs Idelalisib Plus Rituximab in Chronic Lymphocytic Leukemia: A Propensity-Matched Real-World Analysis

Pirtobrutinib's Cardiac Adverse Reactions: An Early Pharmacovigilance Study